2024
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Frutos A, Price A, Harker E, Reeves E, Ahmad H, Murugan V, Martin E, House S, Saade E, Zimmerman R, Gaglani M, Wernli K, Walter E, Michaels M, Staat M, Weinberg G, Selvarangan R, Boom J, Klein E, Halasa N, Ginde A, Gibbs K, Zhu Y, Self W, Tartof S, Klein N, Dascomb K, DeSilva M, Weber Z, Yang D, Ball S, Surie D, DeCuir J, Dawood F, Moline H, Toepfer A, Clopper B, Link-Gelles R, Payne A, Chung J, Flannery B, Lewis N, Olson S, Adams K, Tenforde M, Garg S, Grohskopf L, Reed C, Ellington S, Collaborators C, Collaborators C, Lauring A, Arndorfer J, Bride D, Peltan I, Mohr N, Hager D, Prekker M, Mohamed A, Johnson N, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughan I, Mosier J, Safdar B, Harris E, Chappell J, Stewart L, Swan S, Piedra P, Sahni L, Englund J, Zerr D, Hickey R, Williams J, Rohlfs C, Schlaudecker E, Dosdos D, Moffatt M, Schuster J, Weltmer K, Szilagyi P, Curley T, Mills J, Faryar K, Salata R, Geffel K, Nowalk M, Murthy K, Rose S, Smith M, Wickersham B, Williamson B, Bontrager N, Williams O, Kramer J, Nordstrom L, Monto A, Vaughn I, Dickerson M, McLean C, Noble E, Ray C, Sumner K, Essien I, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Bezi C, Contreras R, Davis G, Lewin B, Mahale P, Patrick R, Qian L, Rayens E, Reyes I, Ryan D, Salas S, Sy L, Yeh M, Zeng X, Fireman B, Goddard K, Hansen J, Jacobson K, Timbol J, Zerbo O, Dunne M, Zhuang Y. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity And Mortality Weekly Report 2024, 73: 168-174. PMID: 38421935, PMCID: PMC10907036, DOI: 10.15585/mmwr.mm7308a3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChildHumansInfluenza VaccinesInfluenza, HumanSeasonsVaccine EfficacyConceptsVaccine effectivenessInfluenza vaccineInfluenza virus infectionInfluenza-associated hospitalizationsAnnual influenza vaccinationSeasonal influenza vaccineTest-negative case-control study designCase-control study designOutpatient visitsInfluenza VEInfluenza BInfluenza seasonInfluenza APediatric patientsInfluenzaVirus infectionOutpatient settingMonthsVaccinePatientsStudy designHospitalAdultsVisitsUnited States
2016
Microvascular Dysfunction as Opposed to Conduit Artery Disease Explains Sex-specific Chest Pain in Emergency Department Patients With Low to Moderate Cardiac Risk
Safdar B, Ali A, D’Onofrio G, Katz SD. Microvascular Dysfunction as Opposed to Conduit Artery Disease Explains Sex-specific Chest Pain in Emergency Department Patients With Low to Moderate Cardiac Risk. Clinical Therapeutics 2016, 38: 240-255.e1. PMID: 26778090, DOI: 10.1016/j.clinthera.2015.12.010.Peer-Reviewed Original ResearchConceptsChest painControl subjectsMicrovascular dysfunctionArtery diseaseObstructive coronary artery diseaseCommon emergency department presentationConduit vessel functionCoronary artery vasomotionTransient forearm ischemiaAcute chest painCardiac risk factorsPersistent chest painAcute coronary syndromeBrachial artery diameterFramingham risk scoreProspective cohort studyChest pain centerSystolic blood pressureAsymptomatic healthy volunteersCoronary artery diseaseEmergency department presentationsBrachial artery reactivityPeripheral microvascular dysfunctionHigh-resolution ultrasoundArtery dysfunction